Major
Probable
Mô tả
Aripiprazole acts as a partial D2 agonist/antagonist and can oppose levodopa's dopaminergic therapy, worsening Parkinson's disease symptoms.
Cơ chế
Aripiprazole's partial D2 agonism results in net D2 receptor blockade in the context of high dopamine from levodopa therapy, impairing motor function.
Ý nghĩa lâm sàng
Parkinson's patients treated with dopaminergic therapy can experience marked motor deterioration when any D2-acting antipsychotic is initiated.
Xử trí
Avoid aripiprazole in Parkinson's disease; use medications with minimal D2 blockade for psychosis treatment in these patients.